Get Support

Learn Mode

GH - Guardant Health Inc

21

$90.36

$4.66 (5.438%)

At market close

$91.94

$1.58 (1.747%)

After Hours 4/17/26, 10:56 PM

3.10/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

GH

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$11.85B

Industry

Health Care

EPS (TTM)

-$3.23

P/E (TTM)

0.00

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

12.07

P/B

0.00

Diluted Shares

128.69M

Ex-Dividend

--

Next Earnings

04-30

Forward P/E

0.00

Payout Ratio

--

P/FCF (TTM)

0.00

FCF Yield

--

Earnings Yield

-3.51%

52 Week Range

Score Card

Explore Scores Tab

3.10

Average

Guardant Health Inc has grown revenue at 32.88% over the past year, which is strong growth. Also, it has more cash than current liabilities meaning it has enough cash to handle all its debts within the next year, if it wanted to.

Valuation Model

Key Score

1.00

Very Bad

Management

4.00

Good

Growth

3.00

Average

Profitability

5.00

Very Good

Fin. Health

3.00

Average

Dividends

--

--

Analyst

5.00

Very Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

3 new filings were in the last 7 days

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-16 19:58:53

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-16 19:58:04

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-04-16 16:01:18

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-07 17:40:03

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-04-06 16:03:54

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 17:24:14

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 17:23:39

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 17:22:58

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 17:22:18

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 17:21:45

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 17:21:07

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 17:20:32

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-07

High:

$189.00

109.2%

Avg:

$132.26

46.4%

Low:

$64.07

-29.1%

(% change is relative to the current stock price: $90.36)

Analyst Recommendations

Go to Analyst Tab

4.29

Very Good

41%

Strong Buy (14)

47%

Buy (16)

12%

Hold (4)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://guardanthealth.com/
Address
3100 Hanover Street, Palo Alto CALIFORNIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1576280

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 2,490 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

IPO Date

2018-10-04

Industry

Health Care

Total Employees

2,490

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Health Care Providers & Services

GICS Sub

Health Care Services

GICS Sector

Health Care

GICS Group

Health Care Equipment & Services